Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma

Hematol Oncol Clin North Am. 2024 Apr;38(2):383-406. doi: 10.1016/j.hoc.2023.12.004. Epub 2023 Dec 28.

Abstract

Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.

Keywords: B cell maturation antigen (BCMA); Chimeric antigen receptor Tcells (CARTs); Cytokine release syndrome (CRS); Multiple myeloma; Relapsed/refractory multiple myeloma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Cell Maturation Antigen
  • Humans
  • Immunotherapy, Adoptive
  • Multiple Myeloma* / pathology
  • Multiple Myeloma* / therapy
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen
  • B-Cell Maturation Antigen